AXSM
Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$207.78
−3.03%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$212.78
From 52W high−18.57%
Volume846276.00
Market cap$10.88B
P/E (TTM)—
P/S (TTM)14.0x
Div yield—
Key dataSep 18, 2026
Open
$212.78
From 52W high
−18.57%
Volume
846276.00
Market cap
$10.88B
ValuationView details →
P/E (Fwd)
1239.7x
EV/EBITDA
−60.0x
P/E (TTM)
—
RSI (14)
47.3
MomentumView details →
1D Return
−3.03%
YTD Return
+14.51%
SummaryUpdated Jun 1, 2026
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company founded in 2012 and headquartered in New York. The company went public in 2015 and focuses on developing and commercializing novel therapies for central nervous system (CNS) disorders. Axsome has successfully transitioned from a pure development-stage company to a commercial-stage biopharmaceutical company with multiple approved products generating significant revenue growth.
Similar companies
Latest newsMore news →
Axsome Therapeutics presented ten posters, including new data in major depressive disorder and Alzheimer's disease agitation, at Psych Congress 2026 in New Orleans on September 17, 2026.3d agoAxsome Therapeutics began dosing in the Phase III SUMMIT study of AXS-05 for smoking cessation in adults.19d agoBlackRock Inc. acquired a new minority stake in Axsome Therapeutics, Inc., buying 3,103,708 shares valued at approximately $759.70 million during the second quarter, as disclosed in its 13F filing with the SEC.28d ago